The Centers for Disease Control and Prevention's new guidelines for sexually transmitted diseases stress the importance of early screening, diagnosis and treatment.
The Centers for Disease Control and Prevention's new guidelines for sexually transmitted diseases stress the importance of early screening, diagnosis and treatment.
The "1998 Guidelines for Treatment of Sexually Transmitted Diseases," updated for the first time since 1993, address several points raised in the Institute of Medicine's 1997 report on the epidemic of STDs in the United States, including consistency and adequacy of care.
Notable changes in treatment outlined in the guidelines include endorsement of single-dose oral therapies for nearly all common, curable STDs.
The guidelines also draw attention to improved treatments for herpes and human papilloma virus. New, recommended therapies may be applied by patients themselves, and may reduce the emotional stress associated with sexually transmitted diseases.
The Centers for Disease Control and Prevention recommends implementing simple urine tests in clinical and non-clinical settings to test for chlamydia. These newer tests may be especially effective in testing in high schools, for example, where large groups of adolescents might be tested. Adolescents, the guidelines note, are at greatest risk for the infection. In one study, as many as one in eight teenage girls tested positive for chlamydia.
The guidelines also recommend more aggressive vaccination of sexually active young people, who are at high risk for hepatitis A and hepatitis B.
Finally, the newer guidelines detail the advances possible in the treatment of STDs during pregnancy. Newer treatments for chlamydia cause fewer side effects, and better screening and treatment of bacterial vaginosis among women with histories of preterm births reduces the number of infants born prematurely as a result of the disease.
Identifying and treating STDs in the estimated 12 million Americans who are infected with them each year can greatly reduce the risks of infertility, potentially fatal tubal pregnancies and debilitating diseases in infants, according the Centers for Disease Control and Prevention.
It may even reduce the contraction and spreading of HIV among women.
The Centers for Disease Control and Prevention will disseminate the new guidelines more aggressively than in years past, officials said.
For more information, physicians and other health care professionals may view the complete guidelines on the Internet at www.cdc.gov./nchstp/dstd/dstdp.html, or order by fax, (404) 639-8628. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.